Company Analysis
Sign in

Seres Therapeutics, Inc. (MCRB)

Nasdaq: MCRB · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2014
Full chart Alerts Compare
Grade4.6
◀ Past 3.2● Present 4.7▶ Future 5.3
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Seres Therapeutics, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.6/10
◀ Past3.225% of the headline
● Present4.735% of the headline
▶ Future5.340% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.2/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
0.5/10

Has it survived what it has been through?

3 warning events since 2017; the latest 2024-11-13.

weight 22% of this tense · 5th percentile among 497 sector filers · read for itself

From the record

Seres Therapeutics, Inc.'s filings since 2017 show 3 warning events of 2 kinds: a debt default or acceleration notice (8-K item 2.04, the latest 2024-05-07); a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2024-11-13) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
3.0/10

What has it actually done, year after year?

-30.8% a year over 10 filed years; profitable in 2 of 10.

weight 45% of this tense · 30th percentile among 323 sector filers · read for its customers

From the record

Seres Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $22 million in fiscal 2016 to $789 thousand in fiscal 2025, down 30.8% a year; it rose in 3 of 7 years; the deepest fall was 100% from fiscal 2021 to fiscal 2023; net income was positive in 2 of 10 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-30.8%bottom 10% of its family
  • the share of years revenue rosebottom 26% of its family
  • the share of filed years with a profittop 27% of its family
  • the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
5.2/10

How has it treated the people who own it?

SI estimate 5.2/10, confidence 35 of 100 (one part).

weight 33% of this tense · 52nd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 48% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Seres Therapeutics, Inc.'s shareholder treatment is put at 5.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 48% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.7/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
5.6/10

Is it financially healthy right now?

ROE 13%: 13¢ of profit per shareholder dollar. Leverage 68%: owes 68¢ per asset dollar.

weight 45% of this tense · 56th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Seres Therapeutics, Inc. earned about 13 cents of profit for every dollar of shareholders' money. Leverage: it owed about 68 cents per dollar of assets, and net share issuance: its share count grew 14.2% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 21% of its family
  • return on equitytop 11% of its family
  • the share count against the year beforetop 43% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
4.2/10

How strong is its position in its industry?

bottom 42% of 315 in its family; net margin 721.9%.

weight 22% of this tense · 42nd percentile among 315 sector filers · read for its customers

From the record

Seres Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $789 thousand in fiscal 2025 ranks in the bottom 20% by size; a net margin of 721.9% ranks in the top 1%; revenue growth of -52% a year over the last 3 filed years ranks in the bottom 8% (its annual reports).

What it rests on

  • revenue against the family$789,000bottom 20% of its family
  • net margin721.9%top 1% of its family
  • three-year revenue growth-52.0%bottom 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
3.9/10

What are the people in charge doing?

bottom 39% of 315 in its family for leadership; chief executive since 2026.

weight 33% of this tense · 39th percentile among 315 sector filers · read for its shareholders

From the record

Seres Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Kender, Richard N (Interim Chief Executive Officer, as filed), filing under that title since 2026-03-06, 8 months (bottom 11% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 7.8 years (top 21%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 27%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge9 in three years among 13 peoplebottom 27% of its family
  • the median years the people in charge have filed7.8 yearstop 21% of its family
  • the chief executive's years on the record8 monthsbottom 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

5.3/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed
8.2/10

How much room does it have to grow?

top 18% of 273 in its family for room to expand.

weight 33% of this tense · 82nd percentile among 273 sector filers · read for itself

From the record

Seres Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $46 million against no long-term debt tagged leaves 33.1% of its assets as net cash, top 44% of its family; cash from operations less capital spending is 109.6% of revenue (top 1%); research spending of 6218% of revenue (top 9%) (its annual report).

What it rests on

  • cash less debt against assets33.1%top 44% of its family
  • cash from operations less capital spending against revenue109.6%top 1% of its family
  • research spending against revenue6218.0%top 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
1.6/10

What could actually drive growth from here?

bottom 16% of 306 in its family for growth drivers.

weight 45% of this tense · 16th percentile among 306 sector filers · read for its customers

From the record

Seres Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -52% a year over the last three filed years against -30.8% over all 10, slowing (bottom 26% of its family); research spending grew -23.5% a year (bottom 17%); capital spending grew -70.5% a year (bottom 6%) (its annual reports). Seres Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span-21.1 points a yearbottom 26% of its family
  • three-year growth of research spending-23.5%bottom 17% of its family
  • three-year growth of capital spending-70.5%bottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
8.5/10

Did its newest year beat what its own record pointed to?

SI estimate 8.5/10, confidence 35 of 100 (one part).

weight 22% of this tense · 85th percentile among 284 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, net income against the prior three years' average, which ranks in the top 15% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: net income against the prior three years' average, the one part on file, ranked among 284 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Seres Therapeutics, Inc.'s expectations vs reality is put at 8.5 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the top 15% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton MCRB · research, not advice